8-K: Connect Biopharma to Terminate ADR Program, Transition to Direct Nasdaq Listing

Connect Biopharma Holdings Limited announced the termination of its American Depositary Receipt (ADR) program and plans for a direct listing of its ordinary shares on Nasdaq under the existing symbol CNTB.

Summary

• Connect Biopharma Holdings Limited instructed Deutsche Bank Trust Company Americas to terminate the Deposit Agreement dated March 18, 2021.
• The Deposit Agreement governs the rights and obligations related to the company's American Depositary Shares (ADSs) listed on the Nasdaq Global Market.
• The ADR program and Deposit Agreement are expected to terminate on or about September 2, 2025.
• Upon termination, ADSs will be mandatorily cancelled and exchanged for Ordinary Shares at a one-for-one ratio.
• Immediately following the ADR program termination, the company plans to list its Ordinary Shares directly on Nasdaq (Substitution Listing).
• Upon effectiveness of the Substitution Listing, ADSs will cease to be listed on Nasdaq, and Ordinary Shares will commence trading under the existing symbol CNTB.
• A press release announcing these plans was issued on July 21, 2025.

Sentiment

Score: 6

Explanation: The announcement is largely administrative, detailing a planned transition from an ADR program to a direct listing of ordinary shares. While it introduces some administrative changes for investors, it maintains the company's Nasdaq listing under the same ticker, which is a neutral to slightly positive outcome for continuity. There are no immediate financial implications or operational updates, making the sentiment moderately positive due to clarity and continuity.

Positives

• The company plans to maintain its listing on Nasdaq through a direct substitution of Ordinary Shares for ADSs, ensuring continued market access.
• The Ordinary Shares will trade under the existing ticker symbol CNTB, providing continuity for investors.
• The exchange ratio is one-for-one, simplifying the transition for current ADR holders.

Negatives

• Current holders of American Depositary Shares (ADSs) will experience a mandatory cancellation of their ADSs and conversion to Ordinary Shares, which may require administrative action or understanding on their part.
• The termination of the ADR program could lead to temporary confusion or administrative burden for some investors unfamiliar with the process of converting ADSs to ordinary shares.

Risks

• Reliance on the Depositary to provide notice of the termination of the ADR program.
• The company must complete the process with Nasdaq to effect the Substitution Listing.
• Drug development and commercialization involve a high degree of risk.
• Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.

Future Outlook

The company expects the ADR program and Deposit Agreement to terminate on or about September 2, 2025, at which time ADSs will be mandatorily cancelled and exchanged for Ordinary Shares at a one-for-one ratio. Immediately following this, the company plans to list its Ordinary Shares directly on Nasdaq, with trading commencing under the existing symbol CNTB.

Management Comments

• On July 21, 2025, the Company issued a press release announcing its plans to terminate the ADR program and the Deposit Agreement and to effect the Substitution Listing.

Industry Context

This administrative change reflects a company's decision to streamline its public listing structure, moving from an ADR program to a direct listing of ordinary shares. Such transitions can occur for various reasons, including cost efficiency, simplification of corporate structure, or alignment with investor preferences, and are not uncommon for companies with international origins listed on U.S. exchanges.

Corporate Governance

Stakeholder Impact

• Shareholders (ADS holders): Will experience a mandatory conversion of their ADSs to Ordinary Shares at a one-for-one ratio. They will continue to hold shares listed on Nasdaq under the same ticker symbol.
• Deutsche Bank Trust Company Americas (Depositary): Will cease its role as Depositary under the terminated agreement.

Next Steps

• The Depositary will distribute a notification to all holders and beneficial owners of ADSs regarding the termination of the ADR program.
• The company will complete the process with Nasdaq to effect the Substitution Listing.

Key Dates

Recommendation

Keywords

Connect Biopharma, CNTB, ADR program termination, American Depositary Shares, Ordinary Shares, Nasdaq listing, direct listing, SEC filing, 8-K, corporate governance, stock exchange, biopharma